The search for optimal treatment in relapsed and refractory acute myeloid leukemia.
Despite the significant progress in the treatment of AML during the last 5-10 years, 20-40% of patients still do not achieve remission with standard induction therapy. In addition, 50-70% of patients in CR are likely to relapse. A major limitation of successful AML therapy is intrinsic or acquired drug resistance. Several pharmacological inhibitors of mechanisms inducing chemoresistance in leukemic cells have been investigated. New cytotoxic drugs, agents with novel mechanisms of action, and new treatment strategies are currently being investigated. The management of refractory or relapsed AML patients is reviewed in this study.
Robak
Tadeusz
T
Department of Hematology, Medical University of Lódź, Copernicus Hospital, Poland. robaktad@csk.am.lodz.pl
Wrzesień-Kuś
Agata
A
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy*; D011379:Prognosis; D012074:Remission Induction / Q000379:methods; D016879:Salvage Therapy; D033581:Stem Cell Transplantation
D000970:Antineoplastic Agents